Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12560MR)

This product GTTS-WQ12560MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets Canlupfam NGF gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001194950.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403402
UniProt ID F1PDQ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12560MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12774MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ8978MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ15500MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ14485MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ13359MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ10000MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ9415MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ2433MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 145
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW